Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Meiji Expands Cocoa Market With Generous Investment

Oh how sweet it is! Japanese confectioner Meiji is expanding its high-cocoa chocolate products, an investment of 27 billion yen, or $245 million USD. Part of the investment includes upgrading their factories. Euromonitor International, a global market research agency, reports that health and wellness trends and the Japan’s ageing population have been the inspiration for…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want MarketScale to feature Healthcare?

Book a 15-minute demo and we'll map your Healthcare expertise to the content buyers are searching for.

Book a demo

Oh how sweet it is! Japanese confectioner Meiji is expanding its high-cocoa chocolate products, an investment of 27 billion yen, or $245 million USD. Part of the investment includes upgrading their factories.

Euromonitor International, a global market research agency, reports that health and wellness trends and the Japan’s ageing population have been the inspiration for the increased demand.

In a statement released from the company, Meiji says they “will continue to invest heavily in research and development in the forecast period, as it seeks to tailor its range of products in line with changing consumer needs.The company is likely to focus on health and wellness products within packaged food, particularly those that appeal to Japan’s increasing number of elderly consumers.”

The company says they also recognize the challenges that population ageing and decline pose to Japan and will focus on boosting packaged food profits by adding value.

And chocolate isn’t their only focus. Meiji will also invest in expanding its production capacity in key growth areas such as yogurt, as well.

Meiji projects that this investment will bolster sales for this fiscal year, and projects an increase from $935 million USD in 2017, to $956 million by March of 2018.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Health systems are spending big on EHRs and AI while governance gaps widen

Health systems are spending big on EHRs and AI while governance gaps widen

Health systems are investing heavily in electronic health records (EHRs) and artificial intelligence (AI). However, there are notable governance gaps in AI implementation in hospitals. Many hospitals lack dedicated platforms for AI testing and reimbursement issues for AI remain unresolved.

  • 01Health systems are making significant financial investments in electronic health records and AI technology.
  • 02AI reimbursement policies remain unclear, posing challenges for healthcare providers.
  • 03Most hospitals do not have dedicated platforms for testing AI applications.

Aug 17, 2026

Health IT spending, AI gaps, and Epic price tags signal a volatile 2026 for hospital CIOs

Health IT spending, AI gaps, and Epic price tags signal a volatile 2026 for hospital CIOs

The healthcare sector in 2026 is expected to see significant challenges regarding IT spending, especially with electronic health record (EHR) projects that surpass $175 million. There are also gaps in testing artificial intelligence (AI) technologies and an increase in turnover among Chief Information Officers (CIOs), signaling potential volatility within hospital IT departments. These factors are reshaping the pressures on hospital CIOs as they plan for the future.

  • 01EHR projects are exceeding $175 million, causing financial strain on hospital IT budgets.
  • 02There is a notable gap in AI testing and implementation within the healthcare sector.
  • 03Chief Information Officer turnover is rising, contributing to instability in hospital IT leadership.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512